Compositions comprising methylphenidate-prodrugs, processes of making and using the same
The present technology is directed to compositions comprising d-threo-methylphenidate conjugates and/or unconjugated methylphenidate. The present technology also relates to compositions and oral formulations comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof. The present technology additionally relates to a pharmaceutical kit containing the composition comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof.
1. A method of treating excessive daytime sleepiness associated with central hypersomnolence disorders, obstructive sleep apnea, or a shift work disorder, in a human or animal subject comprising administering to the human or animal subject a composition comprising a compound, wherein the compound is a conjugate of d-methylphenidate having the following chemical formula:
at least one salt thereof, or mixture thereof.
2. The method of claim 1 , wherein the central hypersomnolence disorder is selected from the group consisting of narcolepsy type 1 (with cataplexy), narcolepsy type 2, idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia due to a medical condition, hypersomnia due to a medication or substance, hypersomnia associated with a psychiatric condition, and insufficient sleep syndrome.
3. The method of claim 1 , wherein the at least one salt of the compound is at least one pharmaceutically or therapeutically acceptable salt form or salt mixture thereof.
4. The method of claim 3 , wherein the at least one pharmaceutically or therapeutically acceptable salt form of the compound is selected from the group consisting of acetate, l-aspartate, besylate, bicarbonate, carbonate, d-camsylate, l-camsylate, citrate, edisylate, formate, fumarate, gluconate, hydrobromide, bromide, hydrochloride, chloride, d-lactate, l-lactate, d,l-lactate, d,l-malate, l-malate, mesylate, pamoate, phosphate, succinate, sulfate, bisulfate, d-tartrate, martrate, d,l-tartrate, meso-tartrate, benzoate, gluceptate, d-glucuronate, hybenzate, isethionate, malonate, methylsulfate, 2-napsylate, nicotinate, nitrate, orotate, stearate, tosylate, thiocyanate, acefyllinate, aceturate, aminosalicylate, ascorbate, borate, butyrate, camphorate, camphocarbonate, decanoate, hexanoate, cholate, cypionate, dichloroacetate, edentate, ethyl sulfate, furate, fusidate, galactarate, galacturonate, gallate, gentisate, glutamate, glutarate, glycerophosphate, heptanoate, hydroxybenzoate, hippurate, phenylpropionate, iodide, xinafoate, lactobionate, laurate, maleate, mandelate, methanesulfonate, myristate, napadisilate, oleate, oxalate, palmitate, picrate, pivalate, propionate, pyrophosphate, salicylate, salicylsulfate, sulfosalicylate, tannate, terephthalate, thiosalicylate, tribrophenate, valerate, valproate, adipate, 4-acetamidobenzoate, camsylate, octanoate, estolate, esylate, glycolate, thiocyanate, undecylenate, hydroxide, hydrogen sulfite (bisulfite), benzene sulfonate, hypophosphite, bromate, iodate, chlorate, fluoride, nitrite, and combinations thereof.
5. The method of claim 4 , wherein the pharmaceutically or therapeutically acceptable salt form of the compound has the following structure:
6. The method of claim 1 , wherein the composition is in a dosage form selected from the group consisting of a sublingual, a gummy, a chewable tablet, a rapidly dissolving tablet, a tablet, a capsule, a caplet, a troche, a lozenge, an oral powder, a solution, a thin strip, an oral thin film (OTF), an oral strip, a rectal film, a syrup, a suspension, and a suppository.
7. The method of claim 1 , wherein the composition is formulated for oral administration.
8. The method of claim 1 , wherein the composition provides a dose amount that is the molar equivalent to a dose from about 0.1 mg to about 500 mg d-methylphenidate hydrochloride per dose.
9. The method of claim 1 , wherein the composition is provided in a unit dose form, blister pack, roll, or bulk bottle.
10. The method of claim 9 , wherein the unit dose form provides an amount of d-methylphenidate that is molar equivalent to about 0.5 mg to about 500 mg d-methylphenidate hydrochloride.
11. The method of claim 1 , wherein the composition further comprises one or more excipients or one or more additional pharmaceutically active ingredients.
12. The method of claim 11 , wherein the excipients are selected from the group consisting of antiadherents, binders, coatings, disintegrants, gel forming agents, fillers, flavors and colors, glidants, lubricants, preservatives, sorbents, and sweeteners.